Objectives 1) Outline the structure and the pharmacology of TNF inhibitors (full lenth monoclonal antibodies, Fc-TNFR fusion protein, PEGylated Fab) that are currently used
2) Discuss the dose-response relationship and the sources of pharmacokinetics and pharmacokinetic-pharmacodynamic variability
3) Focus on the effect of inflammation on pharmacokinetics of TNF inhibitors and the potential interest to adapt the dosage of TNF inhibitors according to the patient's disease activity
Denis Mulleman, M.D., Ph.D., is professor of rheumatology at the University of Tours. He is member of the CNRS research unit 7292 (team 1: “Antibodies, Fc receptors and clinical responses”). His main research interest is to characterize the concentration-response relationship of anti-TNF monoclonal antibodies and Fc-containing fusion proteins to help clinicians personalize drug administration (therapeutic drug monitoring).
Disclosure of Interest D. Mulleman Grant/Research support from: Abbott, Consultant for: MSD, Pfizer